Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone

BACKGROUND: To compare the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatment in newly diagnosed multiple myeloma (MM). METHODS: This was a single‐center retrospective analysis in Xiangtan Central Hospital. A total of 52 newly d...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Zhongjun, Chen, Fang, Liu, Ping, Luo, Zimian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939219/
https://www.ncbi.nlm.nih.gov/pubmed/36052569
http://dx.doi.org/10.1002/cam4.5198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939219/
https://www.ncbi.nlm.nih.gov/pubmed/36052569
http://dx.doi.org/10.1002/cam4.5198

Ejemplares similares